SynthesisFrontiers in pharmacology2025
Safety and efficacy of different JAK inhibitors in the treatment of inflammatory bowel disease: a network meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Stress-Induced (Takotsubo) Cardiomyopathy Associated With Upadacitinib Induction Therapy in Severe Crohn's Disease.ACG case reports journal · 2026Article
- Highlights of the 2026 European Crohn's and Colitis Conference: redefining the IBD care continuum.Crohn's & colitis 360 · 2026Review
- Safety profile of upadacitinib in inflammatory Bowel disease: a dual-source pharmacovigilance study integrating FAERS signal detection and real-world clinical cohort analysis.Frontiers in pharmacology · 2026Article
- Development Trends of Janus Kinase Inhibitors (JAKi) Over Three Decades: From Common to Rare Diseases.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeting the Janus kinase (JAK) signaling pathway is a new way to treat inflammatory bowel disease (IBD). This network meta-analysis aimed to compare the efficacy and safety of various JAK inhibitors, including brepocitinib, filgotinib, ivarmacitinib, peficitinib, ritlecitinib, tofacitinib, and upadacitinib, in patients with IBD. The analysis included patients with both Crohn's disease (CD) and ulcerative colitis (UC). We systematically searched PubMed, Embase, the Cochrane Library, and the Web of Science for randomized controlled trials evaluating JAK inhibitors in patients with CD or UC up to 4 May 2024. A pooled analysis of UC and CD was performed. The primary outcome was clinical remission. Secondary outcomes included clinical response, endoscopic remission, endoscopic response, endoscopic improvement, adverse events (AEs), serious adverse events (SAEs), AEs leading to treatment discontinuation, and infections. Ranking was assessed using the surface under the cumulative ranking curve (SUCRA) probabilities. Ritlecitinib exhibited the highest SUCRA probabilities for clinical remission (88.7%), clinical response (86.0%), and endoscopic improvement (92.1%). Upadacitinib exhibited superiority in endoscopic remission (85.6%) and response (99.5%), demonstrating moderate efficacy in clinical response (82.2%). A safety analysis revealed comparable AE rates for most agents compared to placebo, except for upadacitinib and brepocitinib. Tofacitinib showed the lowest risk of SAEs (72.3%). Upadacitinib had the lowest discontinuation rate (81.3%). Ivarmacitinib demonstrated optimal infection safety (80.3%). Upadacitinib has the best efficacy-safety profile for IBD, while ritlecitinib's superior efficacy is offset by higher safety risks. Long-term studies are needed to confirm these results. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024595343, Identifier CRD42024595343.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.